Our technology platforms can lead to products that are easier to use for patients and caregivers, while reducing costs for payers and the healthcare system.
The Xeris Solution for Conventional Formulation Limitations
Our proprietary XeriSol™ and XeriJect™ non-aqueous formulation technology platforms are designed to address the limitations of aqueous formulations for certain drugs. The solutions or suspensions formulated using our technology have high stability and solubility.
Ready-to-use injectable, with straightforward administration.
Room-temperature stability, with no refrigeration required.
Small injection volumes due to non-aqueous formulation.
Qualities allow for subcutaneous (SC) or intramuscular (IM) administration.
Our biocompatible non-aqueous injectable solutions or suspensions can be packaged for administration in various commercially available ways:
XeriSol can be used for smaller molecules
The XeriSol formulation technology is best suited for peptides and small molecules that encounter formulation challenges.
An aqueous formulation of a peptide or small molecule is created at an optimal, specific pH. This allows the peptide or small molecule to remain soluble at high concentrations in water.
The solution is dried into a powder and reconstituted in an aprotic, polar (FDA-approved) liquid. The liquid prevents aggregation and fibrillation of the drug substance.
When a ready-to-use XeriSol formulation is injected into a patient, it is effectively placed back into a water environment where it behaves appropriately.
XeriJect can be used for larger molecules
The XeriJect formulation technology is best suited for drugs and biologics consisting of large molecules such as proteins, monoclonal antibodies, and vaccines.
Specialized drying or particle engineering techniques are employed to create powders.
The powders are “wetted” with biocompatible diluents, creating ultra-concentrated, low-volume paste formulations.
The paste formulations are administered via IM or SC using commercially available pens and pumps.
Using XeriJect, we have formulated suspensions with a protein concentration in excess of 400 mg/mL, far exceeding current aqueous formulation systems with maximum achievable protein concentrations of 50–250 mg/mL. Our technology platforms can lead to products that are easier to use for patients and caregivers, while reducing costs for payers and the healthcare system.
Conventional Formulation Limitations
Injectable pharmaceuticals typically rely on liquid (water) to deliver drugs and biologics, but many drugs have low solubility in water and are not stable. There are a number of conventional approaches to address these barriers.
Products are freeze-dried into a powder that must be reconstituted with a liquid diluent prior to use. This is often a challenging multistep procedure, especially in emergency situations.
Reconstituted products may either need to be used immediately or refrigerated, because they begin to break down once combined with water.
Products may require complicated formulation volumes to make them soluble.
Products may require injection volumes that are too large for SC or IM delivery and therefore necessitate intravenous (IV) infusion.
We are proud to announce that as of October 5, 2021,
Xeris Pharmaceuticals, Inc. and Strongbridge Biopharma plc
are subsidiaries of Xeris Biopharma Holdings, Inc.
Not opening? Check to see you have pop-ups enabled or copy link below in a new window.https://ir.xerispharma.com/